P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚...P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚ Product Type Study...

3
Precision’s Unique Experience Product Type Study Phase Indication Services Allogenic CRISPR Engineered T Cells (B Cell malignancy) I Biomarker Assays (flow cytometry, multiplexed cytokine anal, immunogenicity assays) Labs and Translational Service CD19-directed genetically modified autologous T Cell immunotherapy N/A Pediatric and young adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia Training Materials, Presentations, Patient Materials, Scientific Papers, Fact Sheets, Physician Guides, Manuals, Site Training Biopsy neo-antigen T Cell matching patient specific vaccine I/II Melanoma, NSCLC, Head and Neck, Urothelial Carcinoma (TCC), Renal Cell (RCC) Start up, Medical Monitoring, Data Management, Monitoring and Site Management, Biostatistics, Project Management, Safety Allogeneic Multi-Antigen Targeted T Cell Therapy II AML or MDS Project Management, Clinical, Medical Monitoring, Safety, Data Management, Statistics, Medical Writing (CSR), Consultancy and Design Allogeneic T Cell Therapy I Relapsed/Refractory Multiple Myeloma Program Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring Autologous T Cell Therapy I-IIa Advanced Solid or Hematological Cancer Program Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring Autologous T Cell Therapy I Solid Tumours Program Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring Cell therapy- human embryonic stem cell- derived retinal pigment epithelial cells I/IIa Dry AMD PM, Clinical, DM, Biostatistics, MW, Safety, QA Allogeneic Mesenchymal bone marrow cells cell therapy I/II cutaneous photoaging PM, Clinical, DM, Biostatistics, MW, Safety Allogeneic Mesenchymal bone marrow cells- cell therapy IIa heart failure PM, Clinical, DM, Biostatistics, MW, Safety Autologous T Cell Therapy I Solid Tumours Program Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring CAR-T Therapy II/III B Cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma KOL Identification And Engagement, Advisory Board Meetings, Disease State Slide Decks, Branded Speaker Slide Decks, Patient Case Development, Speaker Training, Symposia, Congress Support, Reprint Carriers And Annotated Reprints, Technical Operations Training Materials, Sales Training, Patient Services Materials And Call Center Training Cell therapy- human embryonic stem cell- derived retinal pigment epithelial cells I/IIa Dry AMD PM, Clinical, DM, Biostatistics, MW, Safety, QA CELL THERAPY STUDY EXPERIENCE

Transcript of P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚...P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚ Product Type Study...

Page 1: P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚...P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚ Product Type Study Phase Indication Services Allogenic CRISPR Engineered T Cells (B Cell malignancy)

Precision’s Unique Experience

Product TypeStudy Phase Indication Services

Allogenic CRISPR Engineered T Cells(B Cell malignancy)

IBiomarker Assays (flow cytometry, multiplexed cytokine anal, immunogenicity assays)

Labs and Translational Service

CD19-directed genetically modified autologous T Cell immunotherapy

N/APediatric and young adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia

Training Materials, Presentations, Patient Materials, Scientific Papers, Fact Sheets, Physician Guides, Manuals, Site Training

Biopsy neo-antigen T Cell matching patient specific vaccine

I/IIMelanoma, NSCLC, Head and Neck, Urothelial Carcinoma (TCC), Renal Cell (RCC)

Start up, Medical Monitoring, Data Management, Monitoring and Site Management, Biostatistics, Project Management, Safety

Allogeneic Multi-Antigen Targeted T Cell Therapy

II AML or MDSProject Management, Clinical, Medical Monitoring, Safety, Data Management, Statistics, Medical Writing (CSR), Consultancy and Design

Allogeneic T Cell Therapy IRelapsed/Refractory Multiple Myeloma

Program Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring

Autologous T Cell Therapy I-IIaAdvanced Solid or Hematological Cancer

Program Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring

Autologous T Cell Therapy I Solid TumoursProgram Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring

Cell therapy- human embryonic stem cell-derived retinal pigment epithelial cells

I/IIa Dry AMD PM, Clinical, DM, Biostatistics, MW, Safety, QA

Allogeneic Mesenchymal bone marrow cells cell therapy

I/II cutaneous photoaging PM, Clinical, DM, Biostatistics, MW, Safety

Allogeneic Mesenchymal bone marrow cells- cell therapy

IIa heart failure PM, Clinical, DM, Biostatistics, MW, Safety

Autologous T Cell Therapy I Solid TumoursProgram Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring

CAR-T Therapy II/IIIB Cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma

KOL Identification And Engagement, Advisory Board Meetings, Disease State Slide Decks, Branded Speaker Slide Decks, Patient Case Development, Speaker Training, Symposia, Congress Support, Reprint Carriers And Annotated Reprints, Technical Operations Training Materials, Sales Training, Patient Services Materials And Call Center Training

Cell therapy- human embryonic stem cell-derived retinal pigment epithelial cells

I/IIa Dry AMD PM, Clinical, DM, Biostatistics, MW, Safety, QA

CELL THERAPY STUDY EXPERIENCE

Page 2: P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚...P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚ Product Type Study Phase Indication Services Allogenic CRISPR Engineered T Cells (B Cell malignancy)

Precision’s Unique Experience

Product TypeStudy Phase Indication Services

Gene Therapy II AADC deficiencyPrelaunch Activities, Medical Writing, Congress Activities, Disease State Awareness Campaigns, Advisory Board Meetings, Speaker Training Meetings, Internal Training Materials

Gene TherapyApproved in

2017Leber's congenital amaurosis

Postlaunch Content Development Branded And Disease State Awareness Content, Slide Deck Development, Advisory Board Meetings, Internal Training Materials

Gene Therapy I Glioblastoma at first recurrence Biostatistics

Gene Therapy I Recurrent Malignant Glioma Biostatistics

Gene Therapy IbRecurrent Glioblastoma or Gliosarcoma

Biostatistics

Gene Therapy IIRucurrent Glioblastoma or Gliosarcoma

Biostatistics, Data Management, Safety

Gene Therapy II/IIIRecurrent Glioblastoma / Anaplastic Astrocytoma

Biostatistics

Gene Therapy Ib Solid Tumors or Lymphoma Biostatistics, Data Management, Medical Writing

Gene Therapy I Multiple Biostatistics, Clin Ops, Project Management

Gene Therapy IND, I, II Multiple PK, ADA/TAb, NAb, ELISpot

Gene Therapy I,II,III XLMTM PK, ADA/TAb, NAb, ELISpot

Gene Therapy IND, I, II, III Multiple TAb, NAb, ELISpot, Biostatistics

Gene Therapy Preclinical Multiple Custom ELISpot (AAV)

Gene Therapy I/II Wet AMD NAb Assay, Biodistribution (ddPCR)

Gene Therapy I/II Fanconi Anemia TAb Assay, Biodistribution (ddPCR)

Gene Therapy I/II DMD AAV Tab assay (human), Nab assay, MSD, Nanostring

Gene Therapy III, Commercial OTC Deficiency NAb Assay, Biostatistics, CDx Development, Filing & Commercial Testing

Gene Therapy III, Commercial Hemophilia B NAb Assay, Biostatistics, CDx Development, Filing & Commercial Testing

GENE THERAPY STUDY EXPERIENCE

Product TypeStudy Phase Indication Services

Oncolytic Virus I/II Solid Tumour/ Melanoma Data Management, Biostatistics

Oncolytic Virus II Advanced Solid Tumor (ST)Start Up, Project Management, Medical Monitoring, Monitoring Site Management, Safety, Data Management, Biostatistics, Medical Writing

Oncolytic Virus I Solid Tumour/ Melanoma Start Up, Clinical Monitoring, Data Management, Study Management

Oncolytic Virus I Solid Tumour/ Melanoma Data Management And Clinical Programming, Site Monitoring And Management

Oncolytic Virus II Ovarian Solid TumoursStudy Start Up, Project Management, Site Management, Site Monitoring, Data Management, Biostatistics, Medical Writing, Pharmicovigilance, Medical Monitoring

Oncolytic adenovirus I/II Malignant melanomaProject Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and Site Start Up, Management, and Monitoring

Cancer Vaccine III Prostate Cancer Real-time Flow Cytometry, PBMC isolation, ELISpot

Cancer Vaccine IV Prostate Cancer Cell-based Assay for Efficacy Response

Oncolytic Virus III Advanced Solid Tumor (ST)Start up, Project Management, Medical Monitoring, monitoring site management, safety, Data Management, Biostatistics, Medical Writing

AVV Preclinical X-Linked Myotubular Myopathy Statistical consulting

ONCOLYTIC VIRUS AND VACCINE STUDY EXPERIENCE

Page 3: P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚...P˜˚˛˝˙˝ˆ Uˇ˝˘ E˚˜˝˚ˇ˛˚ Product Type Study Phase Indication Services Allogenic CRISPR Engineered T Cells (B Cell malignancy)

Precision’s Unique Experience

Product TypeStudy Phase Indication Services

Radio Labelled I/IIAdvanced Solid Tumor (ST), Head and Neck, NSCLC

Clinical, Site Management And Monitoring, Safety, Data Management, Biostatistics, Project Management, Medical Monitoring, Clinical Study Report

Radio Labelled II Prostate/Solid tumourStart Up, Project Management, Site Management, Site Monitoring, Data Management, Pharmacovigilance, Medical Writing, Biostatistics

Radio Labelled III Prostate/Solid tumourFeasibility/ Recruitment, Start Up, Project Management, Monitoring And Site Management, Safety, Data Management, Biostatistics, Medical Writing

Radio-labelled Diagnostic Imaging IMetastatic Cancer Expressing NTSR-1

Project Management, Medical Monitoring, Pharmacovigilance, Vendor Management, And Site Start Up, Management, And Monitoring

Product TypeStudy Phase Indication Services

RNA-I therapy I Alport Syndrome Clinical, Project Management, Data Management

RNA-I therapy II/III Alpha 1-Antitrypsin Deficiency Clinical, Project Management, Data Management

RNA-I therapy I Alpha 1-Antitrypsin Deficiency Clinical, Project Management, Data Management

RNA-I therapy II Hepatitis B, Hepatitis D Clinical, Project Management, Data Management

mRNA Preclinical Urea Cycle Disorder Clinical, Project Management, Data Management

RADIO-LABELLED STUDY EXPERIENCE

PRECISION EXPERIENCE IN RNA THERAPIES

Product TypeStudy Phase Indication Services

Chimeric Antigen Receptor T-cell (CAR-T) I/II Solid Tumours Clinical/PM and Biometrics Oversight

Chimeric Antigen Receptor T-cell (CAR-T) I/II Program of Haematology indications Clinical/PM and Biometrics Oversight

Allogenic stem cells I & IIPatients with AML, ALL, MDS post induction or consolidation

Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Site Start Up, Management, and Monitoring, Statistics

Tumor Infiltrating Lymphocytes (TIL) II MelanomaProgram Development, Project Management, Medical Monitoring, Pharmacovigilance, Data Management, Medical Writing, Statistics, Vendor Management, and  Site Start Up, Management, and Monitoring

Gene Modified Donor T-cells I/II Heamatological Malignancies Clinical Monitoring

Autologous CAR-T plus checkpoint inhibitor I Adult T cell leukemia/lymphoma Medical Monitoring

Allogeneic CAR-T ISolid tumor(ovarian, pancreatic, renal)

Medical Monitoring

Tumor Infiltrating lymphocytes (TIL) II Cervical CancerProject Management, Pharmacovigilance, Data Management, Site Start Up, Management, and Monitoring

Tumor Infiltrating Lymphocytes (TIL) II Head and neck cancersProject Management, Pharmacovigilance, Data Management, Site Start Up, Management, and Monitoring

Chimeric Antigen Receptor T-cell (CAR-T) I Multiple Myeloma Protocol Development, Project Management, Pharmacovigilance, Data Management, Vendor Management, and Site Start Up, Management, and Monitoring

Chimeric Antigen Receptor T-cell (CAR-T) I Multiple MyelomaProject Management, Pharmacovigilance, Data Management, Site Start Up, Management, and Monitoring

Autologous T-cell receptor modified therapy II AML and MDS Medical Monitoring

Autologous Chimeric Antigen Receptor T-Cell (CAR-T)

I Pediatric neuroblastoma Medical Monitoring

Autologous Chimeric Antigen Receptor T-Cell (CAR-T)

I Multiple myeloma Medical Monitoring

Allogeneic dendritic cell vaccine II NSCLC Medical Monitoring

Paediatric: primitive neuroectodermal tumors (PNETs) (Brain)

IINeuroectodermal tumours (PNETs Brain)

Stats Programming, Protocol Review/Development, and SAP review.

CELLULAR THERAPY EXPERIENCE WITHIN THE PRECISION TEAM


Red Sea coral reef & marine Aquarium systems complete reef ... · ˘ˇ !!˘ˆ ˛ ˆ ˛ˆ˘ ˜˘ 1 ;! ˘ ˛ $ ˆ ˘ !˜ ˛ ˚˘ ˜ˇ ˘ ˙ ˘ˆ ˇ $1 1˚˜˜, $!ˆ$$ +˜ 9 ˆ˛ ˛ˆ˘

Red Sea coral reef & marine Aquarium systems complete reef ... · ˘ˇ !!˘ˆ ˛ ˆ ˛ˆ˘ ˜˘ 1 ;! ˘ ˛ $ ˆ ˘ !˜ ˛ ˚˘ ˜ˇ ˘ ˙ ˘ˆ ˇ $1 1˚˜˜, $!ˆ$$ +˜ 9 ˆ˛ ˛ˆ˘

› uploads › 2019 › epaper › december › bhopal … · ˇ ˆ˙ ˙ ˆ˙ ˇ ˆ ! ˆ " "ˆ˙ #$ %&’( ˚ ˙) ˘ˇ ˆ * ˙ + , ! ˆ ˆ ˆ ˆˆ˙ $ " ˇ " -! ˆ ˆ˙ ! ˆ " "

› uploads › 2019 › epaper › december › bhopal … · ˇ ˆ˙ ˙ ˆ˙ ˇ ˆ ! ˆ " "ˆ˙ #$ %&’( ˚ ˙) ˘ˇ ˆ * ˙ + , ! ˆ ˆ ˆ ˆˆ˙ $ " ˇ " -! ˆ ˆ˙ ! ˆ " "

˘ ˇ ˆ˙ - Amnesty International€¦ · ^q > _ b@d :* ˆ˛@ 9˜ y 5 :˜ ’ h_ ˇ y˙z j [ ˇ i \ c ]* jb ] = ˙ie!e^# 5 ˇ ‘ ˘ˇ ˆ˙˝˛˚˙˜ ! "#$% &’ (ˆ) $ *+,˙˛-

˘ ˇ ˆ˙ - Amnesty International€¦ · ^q > _ b@d :* ˆ˛@ 9˜ y 5 :˜ ’ h_ ˇ y˙z j [ ˇ i \ c ]* jb ] = ˙ie!e^# 5 ˇ ‘ ˘ˇ ˆ˙˝˛˚˙˜ ! "#$% &’ (ˆ) $ *+,˙˛-

!ˆ ˛˙#˝ ˚ ˚˙˜$% & ˙ ˚˝˙’˝ &˘˜ˇ · 2019-03-15 · and people, and this shows ˘ ˇ ˆ ˙ˇ ˝ ˛ ˚˜ ˚ !˛ " ˇ ˇ # ˝ ˚ ˚ ˜ ˝ ˇ ˚ ˚ $ ˘ˇˆ ˙ ˙ ˆˆ

!ˆ ˛˙#˝ ˚ ˚˙˜$% & ˙ ˚˝˙’˝ &˘˜ˇ · 2019-03-15 · and people, and this shows ˘ ˇ ˆ ˙ˇ ˝ ˛ ˚˜ ˚ !˛ " ˇ ˇ # ˝ ˚ ˚ ˜ ˝ ˇ ˚ ˚ $ ˘ˇˆ ˙ ˙ ˆˆ

M ˜˚˛˝˙ˆ ˇ˘ 5001kubota-bg.com/wp2/wp-content/uploads/2017/12/... · €ˆ˛˝˙ˆ˙ˆ ˙˘ˆ ˙˝˘ˆ ˙˘ ˛ ˆ ˆ ‘ ˆ ˝ ˝˙ ˆ-ˇ˝ ˆ ˙ ˝ˇ ˘ˆ , ˆ˙˝ ˆˇ˘

M ˜˚˛˝˙ˆ ˇ˘ 5001kubota-bg.com/wp2/wp-content/uploads/2017/12/... · €ˆ˛˝˙ˆ˙ˆ ˙˘ˆ ˙˝˘ˆ ˙˘ ˛ ˆ ˆ ‘ ˆ ˝ ˝˙ ˆ-ˇ˝ ˆ ˙ ˝ˇ ˘ˆ , ˆ˙˝ ˆˇ˘

Hou diabetes UIT het oog - ScriptieBank...C' % ˘ ˆ % . ˘ ˇ % % ) % % ˘ ˘ ) 5 ˘ ˇ % ˘ ˆ ˇ % QQ ˘ ˇ ) ˇ ˆ ˇˆ ˘ J % ˇ K) 5 ˘ ˇ ˆ ˇ %% ˇ ˇ ˇˆ % ) ' ˇ % ˇ ˆ

Hou diabetes UIT het oog - ScriptieBank...C' % ˘ ˆ % . ˘ ˇ % % ) % % ˘ ˘ ) 5 ˘ ˇ % ˘ ˆ ˇ % QQ ˘ ˇ ) ˇ ˆ ˇˆ ˘ J % ˇ K) 5 ˘ ˇ ˆ ˇ %% ˇ ˇ ˇˆ % ) ' ˇ % ˇ ˆ

˘ ˇ ˆ˙ ˝˛ ˚˜ ˜ Gladiolus hybrida cv. Oscarplantproduction.scu.ac.ir/article_10101_ed70572d7a... · 129 92 $ % ˜ 1 " # 36 ˘˚ ˜( ˘ˇ ˆ˘˙˝ ) ˘ ˇ ˆ˙ ˝˛ ˚˜ ˜

˘ ˇ ˆ˙ ˝˛ ˚˜ ˜ Gladiolus hybrida cv. Oscarplantproduction.scu.ac.ir/article_10101_ed70572d7a... · 129 92 $ % ˜ 1 " # 36 ˘˚ ˜( ˘ˇ ˆ˘˙˝ ) ˘ ˇ ˆ˙ ˝˛ ˚˜ ˜

Samen sterk - HGW Noëlle Pameijer · Samen sterk. ˜˚˛˝˙ˆ˙˛ˇ˘ ˛ˇ ˙ ˇ ˙˙ˆˇ ˙ ˚˙ˆˇ˛ ˆˇ ˇ˙˛ˇ ˙ˆ˙˛ˇ ˙ ˙ˆˇ ˇ ˛ˇ ˝˙ˆ ˇ ˙ ˆ ˙˛ˇ ˚ ˛ˇ

Samen sterk - HGW Noëlle Pameijer · Samen sterk. ˜˚˛˝˙ˆ˙˛ˇ˘ ˛ˇ ˙ ˇ ˙˙ˆˇ ˙ ˚˙ˆˇ˛ ˆˇ ˇ˙˛ˇ ˙ˆ˙˛ˇ ˙ ˙ˆˇ ˇ ˛ˇ ˝˙ˆ ˇ ˙ ˆ ˙˛ˇ ˚ ˛ˇ

NB CFT NL NOV › ... › Nieuwsbrief_CFT_2007_01_november.pdfˇˆ ˙˝ ˛ ˙ ˚ ˜ ! " # ˇ ! ˚ ˇ $ % ˝ ˇ ˇ $ ˛&˙ˇ˛ ’ ˝ ˙ ˇ ( ˝ ˙ˇ ’ ˘ ˇ ˆ˙ ˝˛ ˚˜ ˜˛ ˆ

NB CFT NL NOV › ... › Nieuwsbrief_CFT_2007_01_november.pdfˇˆ ˙˝ ˛ ˙ ˚ ˜ ! " # ˇ ! ˚ ˇ $ % ˝ ˇ ˇ $ ˛&˙ˇ˛ ’ ˝ ˙ ˇ ( ˝ ˙ˇ ’ ˘ ˇ ˆ˙ ˝˛ ˚˜ ˜˛ ˆ

Harry Potter and the Order of the Phoenix (second draft ... · ˜ + ˘ˆ˛˛ˆ) ˇ .˚ ˆ , ˜ ˜ ˛ ˙ ˜˘ ˚ )˜ ˜ ˇ ˜ +˚ + ˘˛ ˝, ˙ ˆ ˇ * ˛ ˙ ˆ ˙ ˇ ."%% - ˚ ˜

Harry Potter and the Order of the Phoenix (second draft ... · ˜ + ˘ˆ˛˛ˆ) ˇ .˚ ˆ , ˜ ˜ ˛ ˙ ˜˘ ˚ )˜ ˜ ˇ ˜ +˚ + ˘˛ ˝, ˙ ˆ ˇ * ˛ ˙ ˆ ˙ ˇ ."%% - ˚ ˜

Samenvatting De Haes (5) - Medicaˇ • 8 > B˘ˆ ; %&++$%B1+(%+C BC;ˆ B ˘ ˇ1 ˆ ˇ ˇ ; K ; H G C B˘ ˆ

Samenvatting De Haes (5) - Medicaˇ • 8 > B˘ˆ ; %&++$%B1+(%+C BC;ˆ B ˘ ˇ1 ˆ ˇ ˇ ; K ; H G C B˘ ˆ

LeftOvers InfoGraphicImages/LeftOvers+InfoGraphic.pdf˜˚˛˝˙ˆˇ˙˘˚ ˇ ˙ ˆ˙ ˇˇ ˜˚˛˝˙ˆ˚˝ˇ˘ ˝ ˝ ˚ ˝˚˚ ˚˝ ˝ ˚ ˇ ˚˚ ˚˚ ˇ ˚˚ • ˇ ˇ ˇ

LeftOvers InfoGraphicImages/LeftOvers+InfoGraphic.pdf˜˚˛˝˙ˆˇ˙˘˚ ˇ ˙ ˆ˙ ˇˇ ˜˚˛˝˙ˆ˚˝ˇ˘ ˝ ˝ ˚ ˝˚˚ ˚˝ ˝ ˚ ˇ ˚˚ ˚˚ ˇ ˚˚ • ˇ ˇ ˇ

PLAN DU SALON - Rhône-Alpes...eI ˜˚˛˝˙ˆˇ˘ˆ˛ ˜˚˛˝˙ˆˇ˘ˆ˛ ˜˛˘ ˜ ˘ ˙˝˜ˇ ˇ ˙ ˙ ˝ˇ ˛˝ ˘˜˘˝ ˘ ˛˘˝˜˝˛ ˘˛˜ ˛˘ ˙˜ ˝ ˆ ... Spécialités

PLAN DU SALON - Rhône-Alpes...eI ˜˚˛˝˙ˆˇ˘ˆ˛ ˜˚˛˝˙ˆˇ˘ˆ˛ ˜˛˘ ˜ ˘ ˙˝˜ˇ ˇ ˙ ˙ ˝ˇ ˛˝ ˘˜˘˝ ˘ ˛˘˝˜˝˛ ˘˛˜ ˛˘ ˙˜ ˝ ˆ ... Spécialités

˘ ˇ “Judge Arshad Hussain...2020/11/19  · ˘ˇ ˘ ˇ ˇ ˆ ˙˝ ˆ ˙ ˛ ˚ ˚ ˜ ˙! ˆ ˙ ˙˝ ˛˚ ˜˚ˇ" ˆ ˆ ˙ $ % & ˚ ˙˝ ˆ

˘ ˇ “Judge Arshad Hussain...2020/11/19  · ˘ˇ ˘ ˇ ˇ ˆ ˙˝ ˆ ˙ ˛ ˚ ˚ ˜ ˙! ˆ ˙ ˙˝ ˛˚ ˜˚ˇ" ˆ ˆ ˙ $ % & ˚ ˙˝ ˆ

Carolina Final Report-2004.pdfˇˆ " ˘! ˚$ˇ( ˙˝ .’+ˆ˙* ˜ ˝˝ ˘ %˙ ˘ˇ( >#˙˙2˙$ ˇ ˘$ ! +ˇ$ 55555555555555555555 - ˚˝ˆ ˚! ˜ˇ˚%˘ ’ˇ˘*0 ˇ˜˙˚˜˝˙˘.’+ˆ˙*

Carolina Final Report-2004.pdfˇˆ " ˘! ˚$ˇ( ˙˝ .’+ˆ˙* ˜ ˝˝ ˘ %˙ ˘ˇ( >#˙˙2˙$ ˇ ˘$ ! +ˇ$ 55555555555555555555 - ˚˝ˆ ˚! ˜ˇ˚%˘ ’ˇ˘*0 ˇ˜˙˚˜˝˙˘.’+ˆ˙*

L'origine du monde. Gustave Courbet - ScriptieBank · 2018-03-23 · ˇ ˛ . ˇ9 ˇ ˇ k ˇ ˆ˙˝ ' ˛ * ˇ ˇ # ' ˇ ˛ ˜ ' ˇ# ˆ˙˝ ˇ ˛ / e ˇ ˇ

L'origine du monde. Gustave Courbet - ScriptieBank · 2018-03-23 · ˇ ˛ . ˇ9 ˇ ˇ k ˇ ˆ˙˝ ' ˛ * ˇ ˇ # ' ˇ ˛ ˜ ' ˇ# ˆ˙˝ ˇ ˛ / e ˇ ˇ

Transponder install instructions 2018 R4 2˜˚˛˝˙˚˝ˆˇ˘˙ ˝ ˚ ˝˜˚˛˝˙ˆˆ˝ ˇ˘ ˚ˇ ˜˚˛˝˙˜˚˛˜˝˙ˆ˜ˇ˙ˆ˘ ˜˝˙ˆ ˜˜˚˛˝˙ˆˆ˜ ˇ ˙ ˝ ˜ ' ˜˘˙

Transponder install instructions 2018 R4 2˜˚˛˝˙˚˝ˆˇ˘˙ ˝ ˚ ˝˜˚˛˝˙ˆˆ˝ ˇ˘ ˚ˇ ˜˚˛˝˙˜˚˛˜˝˙ˆ˜ˇ˙ˆ˘ ˜˝˙ˆ ˜˜˚˛˝˙ˆˆ˜ ˇ ˙ ˝ ˜ ' ˜˘˙

MD 310 C K16 - Manitowoc Cranes/media/Files/MTW Direct... · 2016. 8. 29. · MD 310 C K16 ˜˚ m ˙ ˆ ˇ ˘ ˘ ˘ ˜ ˙ ˆ ˇ ˘ ˘ ˘ ˜ ˙ ˆ ˇ ˘ ˘ ˘ ˜ ˙ ˆ ˇ ˘ ˘ ˙

MD 310 C K16 - Manitowoc Cranes/media/Files/MTW Direct... · 2016. 8. 29. · MD 310 C K16 ˜˚ m ˙ ˆ ˇ ˘ ˘ ˘ ˜ ˙ ˆ ˇ ˘ ˘ ˘ ˜ ˙ ˆ ˇ ˘ ˘ ˘ ˜ ˙ ˆ ˇ ˘ ˘ ˙

16 ˘ˇˆ˙ ˇ˝˛˚˜ ˝ ˛˛˘˝ˆ˛˘! ˛˚!ˆ˜ˆ 1 › ith › ITH2017-CountryList-ru.pdf · – 16 2017 . ˘ˇˆ˙ ˇ˝˛˚˜, ˝ ˛˛˘˝ˆ˛˘! ˘ ˛˚!ˆ˜ˆ" 1 ˘ ˇˆ ,

16 ˘ˇˆ˙ ˇ˝˛˚˜ ˝ ˛˛˘˝ˆ˛˘! ˛˚!ˆ˜ˆ 1 › ith › ITH2017-CountryList-ru.pdf · – 16 2017 . ˘ˇˆ˙ ˇ˝˛˚˜, ˝ ˛˛˘˝ˆ˛˘! ˘ ˛˚!ˆ˜ˆ" 1 ˘ ˇˆ ,

Articolo STATISTICA - Quaderno 11 03 · ˘ˇˆ ˙˝ˆ˛ ˆ ˚ ˆ ˙˜ ˜ !"#$%% & ˘ˇ’(˜ ˆ ˚˛ ˝ˆ()˜ ˘ˇ’˚˙ ˆ ˙˙ (˘*˜(* +˘ )˜*˛˘*&˜ ˚)˘˙˘ ˙˙ ˘˛+˘,˘+˚

Articolo STATISTICA - Quaderno 11 03 · ˘ˇˆ ˙˝ˆ˛ ˆ ˚ ˆ ˙˜ ˜ !"#$%% & ˘ˇ’(˜ ˆ ˚˛ ˝ˆ()˜ ˘ˇ’˚˙ ˆ ˙˙ (˘*˜(* +˘ )˜*˛˘*&˜ ˚)˘˙˘ ˙˙ ˘˛+˘,˘+˚